期刊文献+

我国中药贸易现状及思考 被引量:18

Current Situation of Export Trade of Traditional Chinese Medicine
下载PDF
导出
摘要 随着中药在国内外的关注度持续上升,其行业发展也迎来了新的契机。本文通过对1989-2015年中药出口的情况进行梳理,从中药产品出口的增长速度、产品结构等角度来分析,并结合中药国际市场的政策法规来探讨中药出口存在的问题,以期为我国中药国际化提供参考。 With the continually increasing domestic and oversea attention of traditional Chinese medicine (TCM),the development of the industry has also ushered in a new opportunity. This paper analyzed TCM exports in 1989-2015, the problems of the export trade of TCM was discussed from the point of view of TCM growth rate,product structure and so on,furthermore combined with the laws and regulations of the international markets. It aims to provide some insight to TCM internationalization.
出处 《中国现代中药》 CAS 2017年第2期278-282,共5页 Modern Chinese Medicine
关键词 中药 贸易 发展 Traditional Chinese medicines trade development
  • 相关文献

参考文献8

二级参考文献31

  • 1吴延兵.市场结构、产权结构与R&D——中国制造业的实证分析[J].统计研究,2007,24(5):67-75. 被引量:142
  • 2FDA. FulyzaqTM (crofelemer) delayed-release tablets, for oral use [EB/OL]. http://www.accessdata.fda.gov/drugsatfda_ docs/nda/2012/202292Orig 1 s000Lbl.pdf.
  • 3FDA. Review classification policy: priority (P) and standard (S) [EB/OL]. (2007-07-16)[2012-02-03]. http://www.fda.gov/downloads/AboutFDA/CentersOffice s/Officeo fMedicalProductsandTobacco/CDER/ManualofP oliciesProcedures/ucm082000.pdf.
  • 4FDA. FulyzaqTM (crofelemer) delayed-release tablets, cross discipline team leader review [EB/OL]. http://www. accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Ori g 1 s000CrossR.pdf.
  • 5FDA. FulyzaqTM (crofelemer) delayed-release tablets, Summary Review [EB/OL]. http://www.accessdata.fda.gov/ drugsatfda_docs/nda/2012/202292Orig 1 s000SumR.pdf.
  • 6陈仲常,余翔.企业研发投入的外部环境影响因素研究—基于产业层面的面板数据分析[J].科研管理,2007,28(2):78-84. 被引量:88
  • 7The European Parliament and the Council of the European Union. Directive 2004/24/EC of the European Parliament and the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/ EC on the Community code relating to medicinal products for human use [J]. Official Journal of the European Union, 2004,47(L-136) :85.
  • 8Peschel W. The use of community herbal monographs to fa-cilitate registrations and authorisations of herbal medicinal products in the European Union 2004-2012 [ J ]. Journal of Ethnopharmacology ,2014,158:471-486.
  • 9European Medicines Agency. Overview of assessment work- Priority list [ EB/OL]. http ://www, ema, europa, eu/docs/ en_ G B/ document_library / Other/2009 /12/W C500017 72 4. pdf, 2015 -07 -24/2015 -09 -23.
  • 10European Medicines Agency. Procedure on management of proposals submitted by interested parties for community list entries or community herbal monographs[ EB/OL]. http:// www. ema. europa, eu/docs/en_GB/documentlibrary/Reg- ulatory_ and_procedural_guideline/ 2009 /12/ W C500016900. pdf,2009-11-12/2015-09-23.

共引文献644

同被引文献280

引证文献18

二级引证文献199

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部